Millennium Management LLC raised its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 160.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 90,436 shares of the company's stock after buying an additional 55,682 shares during the quarter. Millennium Management LLC owned about 0.31% of Dianthus Therapeutics worth $1,972,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $26,000. KLP Kapitalforvaltning AS bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $33,000. KBC Group NV bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $35,000. BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $59,000. Finally, AlphaQuest LLC grew its holdings in shares of Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after purchasing an additional 3,072 shares during the last quarter. 47.53% of the stock is owned by institutional investors.
Dianthus Therapeutics Trading Up 2.1%
NASDAQ:DNTH traded up $0.37 during mid-day trading on Wednesday, hitting $17.96. 160,469 shares of the company's stock were exchanged, compared to its average volume of 275,745. The company has a 50 day simple moving average of $18.89 and a 200-day simple moving average of $21.32. Dianthus Therapeutics, Inc. has a fifty-two week low of $13.37 and a fifty-two week high of $32.27. The firm has a market capitalization of $577.59 million, a P/E ratio of -7.18 and a beta of 1.48.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.81 million. As a group, analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.
Analyst Ratings Changes
Several brokerages recently issued reports on DNTH. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Robert W. Baird decreased their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Guggenheim reaffirmed a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Dianthus Therapeutics presently has a consensus rating of "Buy" and an average price target of $53.00.
View Our Latest Stock Analysis on Dianthus Therapeutics
Dianthus Therapeutics Profile
(
Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Stories

Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.